Cargando…

Sensitivity to systemic therapy for metastatic breast cancer in CHEK2 1100delC mutation carriers

PURPOSE: The role of CHEK2 in DNA repair by homologous recombination suggests that CHEK2-associated breast cancer (BC) patients might be more sensitive to chemotherapy inducing double-strand DNA breaks, but results hereon are lacking. We compared the sensitivity to first-line chemotherapy and endocr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kriege, Mieke, Jager, Agnes, Hollestelle, Antoinette, Berns, Els M. J. J., Blom, Jannet, Meijer-van Gelder, Marion E., Sieuwerts, Anieta M., van den Ouweland, Ans, Collée, J. Margriet, Kroep, Judith R., Martens, John W. M., Hooning, Maartje J., Seynaeve, Caroline
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2015
Materias:	Original Article – Clinical Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4543421/ https://www.ncbi.nlm.nih.gov/pubmed/25958056 http://dx.doi.org/10.1007/s00432-015-1981-7

Ejemplares similares

Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy
por: Kriege, M, et al.
Publicado: (2014)

Breast cancer genomes from CHEK2 c.1100delC mutation carriers lack somatic TP53 mutations and display a unique structural variant size distribution profile
por: Smid, Marcel, et al.
Publicado: (2023)

Genetic modifiers of CHEK2*1100delC associated breast cancer risk
por: Muranen, Taru A., et al.
Publicado: (2016)

CHEK2 (∗)1100delC Mutation and Risk of Prostate Cancer
por: Hale, Victoria, et al.
Publicado: (2014)

CHEK2 1100delC in patients with metachronous cancers of the breast and the colorectum
por: Isinger, Anna, et al.
Publicado: (2006)

CHEK2 1100 delC mutation in Russian ovarian cancer patients
por: Krylova, Nadezhda Yu, et al.
Publicado: (2007)

Genomic profiling of CHEK2*1100delC-mutated breast carcinomas
por: Massink, Maarten P. G., et al.
Publicado: (2015)

The CHEK2(*)1100delC mutation has no major contribution in oesophageal carcinogenesis
por: Koppert, L B, et al.
Publicado: (2004)

Clinical utility of testing for PALB2 and CHEK2 c.1100delC in breast and ovarian cancer
por: Woodward, Emma R., et al.
Publicado: (2021)

CHEK2 1100delC is prevalent in Swedish early onset familial breast cancer
por: Margolin, Sara, et al.
Publicado: (2007)

Frequency of CHEK2*1100delC in New York breast cancer cases and controls
por: Offit, Kenneth, et al.
Publicado: (2003)

A Case of Male Breast Cancer Patient with CHEK2*1100delC Mutation
por: Nguyen, Quan D, et al.
Publicado: (2020)

Risk for contralateral breast cancer among carriers of the CHEK2(*)1100delC mutation in the WECARE Study
por: Mellemkjær, L, et al.
Publicado: (2008)

Mutation screening of BRCA1, BRCA2 and CHEK2*1100delC in Slovak HBOC families
por: Cierniková, S, et al.
Publicado: (2005)

Breast tumors from CHEK2 1100delC-mutation carriers: genomic landscape and clinical implications
por: Muranen, Taru A, et al.
Publicado: (2011)

Frequency of the CHEK2 1100delC mutation among women with early-onset and bilateral breast cancer
por: Ding, Dapeng, et al.
Publicado: (2012)

A search for modifying genetic factors in CHEK2:c.1100delC breast cancer patients
por: Wendt, Camilla, et al.
Publicado: (2021)

Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer‐specific survival
por: Morra, Anna, et al.
Publicado: (2023)

Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival
por: Morra, Anna, et al.
Publicado: (2023)

The CHEK2 1100delC allelic variant is not present in familial and sporadic breast cancer cases from Moroccan population
por: Marouf, Chaymaa, et al.
Publicado: (2015)

CHEK2 c.1100delC mutation is associated with an increased risk for male breast cancer in Finnish patient population
por: Hallamies, Sanna, et al.
Publicado: (2017)

Low frequency of CHEK2 1100delC allele in Australian multiple-case breast cancer families: functional analysis in heterozygous individuals
por: Jekimovs, C R, et al.
Publicado: (2005)

BRCA1, BRCA2 and PALB2 mutations and CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal and/or triple negative breast cancer
por: Francies, F. Z., et al.
Publicado: (2015)

Genomic profiling of pelvic genital type leiomyosarcoma in a woman with a germline CHEK2:c.1100delC mutation and a concomitant diagnosis of metastatic invasive ductal breast carcinoma
por: Thibodeau, My Linh, et al.
Publicado: (2017)

Recurrent HOXB13 mutations in the Dutch population do not associate with increased breast cancer risk
por: Liu, Jingjing, et al.
Publicado: (2016)

Corrigendum: Genomic profiling of pelvic genital type leiomyosarcoma in a woman with a germline CHEK2:c.1100delC mutation and a concomitant diagnosis of metastatic invasive ductal breast carcinoma
por: Thibodeau, My Linh, et al.
Publicado: (2018)

Familial breast cancer and the hCHK2 1100delC mutation: assessing cancer risk
por: Varley, Jenny, et al.
Publicado: (2003)

CHEK2 C1100del mutation associated with papillary renal cell carcinoma type II
por: Lopez, Santiago J., et al.
Publicado: (2023)

The 29.5 kb APOBEC3B Deletion Polymorphism Is Not Associated with Clinical Outcome of Breast Cancer
por: Liu, Jingjing, et al.
Publicado: (2016)

The checkpointkinase 2 (CHK2) 1100delC germ line mutation is not associated with the development of squamous cell carcinoma of the head and neck (SCCHN)
por: Scheckenbach, Kathrin, et al.
Publicado: (2010)

Recontacting non-BRCA1/2 breast cancer patients for germline CHEK2 c.1100del pathogenic variant testing: uptake and patient experiences
por: Velthuizen, Mary E., et al.
Publicado: (2021)

Phase relations in the Nb–Ni–Cr system at 1,100 °C
por: Kodentsov, Alexander A., et al.
Publicado: (2012)

A pipeline for copy number profiling of single circulating tumour cells to assess intrapatient tumour heterogeneity
por: Deger, Teoman, et al.
Publicado: (2022)

pi pi phenomenology below 1100 MeV
por: Basdevant, J L, et al.
Publicado: (1972)

1100 words you need to know
por: Bromberg, Murray, et al.
Publicado: (2018)

Timing of risk reducing mastectomy in breast cancer patients carrying a BRCA1/2 mutation: retrospective data from the Dutch HEBON study
por: Wevers, M. R., et al.
Publicado: (2015)

Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers
por: Heemskerk-Gerritsen, Bernadette A. M., et al.
Publicado: (2019)

Post-Operative Appraisal of 1100 Surgical Cases
por: Chand, Ratan
Publicado: (1954)

$\pi$-proton scattering in the energy region 500-1100 MeV
por: Grard, F, et al.
Publicado: (1962)

The Prevalence of CHEK1 and CHEK2 Mutations in Prostate Cancer: a Retrospective Cohort Study
por: Alorjani, Mohammed, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_828025ohissma2vf8j5r97n824